Comments

Biomarin Pharmaceutical

Q: What sector and industry does Biomarin Pharmaceutical (BMRN) operate in?

Biomarin Pharmaceutical is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

BMRNNASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

$68.74

0.010000.01%

Pre-Market: 6:41 PM EDT

Q4 2024 Earnings were released on Wed Feb 19th, after the market close

The most recent conference call was at 16:30 PM, 2 days ago Click to view past webcast

Biomarin Pharmaceutical (BMRN) Forecast

News Earnings Biomarin Pharmaceutical (BMRN) Options Guidance Dividends Analyst Ratings Insider Trades Government Trades Short Interest

Edge Rankings

Want to View Edge Rankings?

Unlock The Hidden Results With Your Benzinga Account Now.

Get Started

Biomarin Pharmaceutical (NASDAQ:BMRN) Stock Quotes, Forecast and News Summary

Biomarin Pharmaceutical Stock (NASDAQ: BMRN) stock price, news, charts, stock research, profile.

Open	-
Close	-
Volume / Avg.	5.00 / 1.52M
Day Range	- - -
52 Wk Range	60.63 - 94.85
Market Cap	$13.10B
P/E Ratio	31.10
Dividend Yield	-
Exchange	NASDAQ
RSI	75
Short Interest	2.38%
Days to Cover	2.31

Recent News

Why Is BioMarin Stock Trading Higher On Thursday?

BioMarin exceeded Q4 earnings expectations, raised 2025 guidance, and projected strong Voxzogo growth. Analysts increased price targets following the results.

Vandana Singh

Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?

Ascendis Pharma beat Q4 earnings and revenue estimates, driven by a $100M Novo Nordisk deal and Yorvipath's EU launch. Goldman Sachs raised its price target.

Vandana Singh

Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?

Eleven large-cap stocks were the worst performers in the last week. Short positions announced for FTAI, revenue updates for MRNA, and price forecasts changed for GME, SNAP, RKLB, NTRA, LLY, ICLR, BNTX, NVO, and BMRN.

Lekha Gupta

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Oct 24

Nov 24

Dec 24

Feb

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.8

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	-
Close	-
Volume / Avg.	5.00 / 1.52M
Day Range	- - -
52 Wk Range	60.63 - 94.85
Market Cap	$13.10B
P/E Ratio	31.10
Dividend Yield	-
Exchange	NASDAQ
RSI	75
Short Interest	2.38%
Days to Cover	2.31

About Biomarin Pharmaceutical Inc.

Sector

Health Care

Industry

Biotechnology

BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture ...

Compare

EPS better than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS better than industry

FAQ

How do I buy Biomarin Pharmaceutical (BMRN) stock?

You can purchase shares of Biomarin Pharmaceutical (NASDAQ:BMRN) through any online brokerage.

View our list of the best stock brokerages

Who are Biomarin Pharmaceutical (BMRN) competitors?

Other companies in Biomarin Pharmaceutical’s space includes: BeiGene (NASDAQ:ONC), Sarepta Therapeutics (NASDAQ:SRPT), Exact Sciences (NASDAQ:EXAS), Neurocrine Biosciences (NASDAQ:NBIX) and Amgen (NASDAQ:AMGN).

What is the forecast, or price target, for Biomarin Pharmaceutical (BMRN) stock?

Biomarin Pharmaceutical has a consensus price target of $97.48.

What is the current price for Biomarin Pharmaceutical (BMRN)?

The stock price for Biomarin Pharmaceutical (NASDAQ: BMRN) is $68.74 last updated February 20, 2025 at 6:41 PM EST.

Does Biomarin Pharmaceutical (BMRN) pay a dividend?

There are no upcoming dividends for Biomarin Pharmaceutical.

When is Biomarin Pharmaceutical (NASDAQ:BMRN) reporting earnings?

Biomarin Pharmaceutical’s Q1 earnings are confirmed for Wednesday, April 23, 2025.

Is Biomarin Pharmaceutical (BMRN) going to split?

There is no upcoming split for Biomarin Pharmaceutical.

What sector and industry does Biomarin Pharmaceutical (BMRN) operate in?

Biomarin Pharmaceutical is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.